SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon.

WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy.

HAMBURG, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XCHG Limited (“XCharge” or the “Company”), (Nasdaq: XCH), a global leader in integrated EV charging solutions, today published its 2024 Environmental, Social and Governance Report (the “2024 ESG Report”). The Report highlights XCharge's achievements and transformative progress toward its commitment to innovate beyond charging by delivering smart and scalable solutions that optimize energy efficiency.

NEW YORK, NY / ACCESS Newswire / October 21, 2025 / Reservoir Media, Inc. (NASDAQ:RSVR) ("Reservoir" or the "Company"), an award-winning independent music company, today announced that it will release financial results for the second fiscal quarter of 2026 ended September 30, 2025, before market open on Tuesday, November 4, 2025. Reservoir will host a conference call to discuss its results at 10 a.m.

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research collaboration and drug supply agreement with Jazz Pharmaceuticals. Under the agreement, Jazz will provide zanidatamab (Ziihera®), a HER2-targeted bispecific antibody, at no cost to Iambic for evaluation in combination with IAM1363, Iambic's brain-penetrant HER2 small-molec.

OMAHA, Neb. & MEXICO CITY--(BUSINESS WIRE)--ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, and Prosa, one of the largest electronic payments networks in Latin America and a technology leader in financial infrastructure, have successfully completed a major infrastructure upgrade—migrating Prosa's clearing house services to a new, state-of-the-art data center in Monterrey powered by ACI's cutting-edge software. Prosa has continuously driven innovation across the.

WINDSOR, Conn.--(BUSINESS WIRE)--SS&C GlobeOp Forward Redemption Indicator.

OMAHA, Neb.--(BUSINESS WIRE)--Valmont® Industries, Inc. (NYSE: VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today reported financial results for the third quarter ended September 27, 2025. President and Chief Executive Officer Avner M. Applbaum commented, “Our third quarter results reflect strong execution on our 2025 priorities and long-term value drivers. The Infrastructure segment delivered solid growth, led.

SAN FRANCISCO--(BUSINESS WIRE)--Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, today announced its most significant AI update yet as part of its 2025 Fall Product Release. Introducing more than 35 new features and updates, Yelp's latest release continues to transform the experience with AI to make local discovery more conversational and personalized. Yelp Assistant will now answer any question about a restaurant, bar, local attraction, retailer and more. M.

VERNON HILLS, Ill.--(BUSINESS WIRE)--CDW Corporation (Nasdaq: CDW) announced today that it will host a webcast conference call to discuss its third quarter 2025 results on Tuesday, November 4, 2025, at 7:30 a.m. CT/8:30 a.m. ET. A live webcast (audio with slides) of the conference call will be accessible at investor.CDW.com. The press release and presentation slides will be posted on this website prior to the call. Please visit the website at least fifteen minutes prior to the call to register.

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced it will release financial results for the third quarter 2025 before the market opens on Tuesday, Nov. 4. Management will host a webcast and conference call that same day at 8:30 a.m. EST (7:30 a.m. CST) to review results. Webcast and Conference Call The conference call will be broadcast live over the Internet. Additionally, a slide presentation will accompany the conferen.

COLLIERVILLE, Tenn.--(BUSINESS WIRE)--Mueller Industries, Inc. (NYSE: MLI) announces results for the third quarter of 2025. Comparisons are to the third quarter of 2024. Net Income of $208.1 million versus $168.7 million Operating Income of $276.1 million versus $206.7 million Net Sales of $1.08 billion versus $997.8 million Diluted EPS of $1.88 versus $1.48 Third Quarter Financial and Operating Highlights: COMEX copper averaged $4.83 per pound during the quarter, which represents a 14.3 percen.

CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). FX-909, a first-in-class orally available small molecule inhibitor of PPARG, the master regulator of the luminal lineage, will be evaluated in combination with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 (programmed cell death receptor-1) therapy, in a new cohort within the company's ongoing Phase 1 study in …

TEL AVIV, Israel , Oct. 21, 2025 /PRNewswire/ -- RADCOM Ltd. (NASDAQ: RDCM) announced today that it will release its financial results for the third quarter, ended September 30, 2025, on Wednesday, 12, November, 2025 before the opening of trade on the Nasdaq Stock Market.

Recurrent Energy's latest solar and energy storage projects support Arizona Public Service's record power needs KITCHENER, ON , Oct. 21, 2025 /PRNewswire/ -- Recurrent Energy, a subsidiary of Canadian Solar Inc. ("Canadian Solar") (NASDAQ: CSIQ) and a global developer, owner, and operator of solar and energy storage assets, today announced it has closed $825 million in construction financing and tax equity for its Desert Bloom Storage and Papago Solar facilities. Nord/LB, Mitsubishi UFJ Financial Group, Inc. (MUFG), CoBank, and Siemens Financial Services provided the construction financing, and Wells Fargo provided the tax equity.

Former Morgan Stanley Executives Jeff Levin and Kunal Soni Join as Partners Levin Named Head of Thoma Bravo Credit MIAMI and NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Thoma Bravo, a leading software investment firm, today announced that Jeff Levin and Kunal Soni have joined the firm as partners on the Thoma Bravo Credit platform. Levin has also been named head of the platform.

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.

CHICAGO--(BUSINESS WIRE)--Accel Entertainment, Inc. (NYSE: ACEL), a leading locals-focused gaming operator partnering with small businesses, local communities, and state governments to provide entertaining, convenient, and safe gaming experiences nationwide, today announced it will release its financial and operating results for the third quarter ended September 30, 2025, after market close on Tuesday, November 4, 2025. The company will host a conference call and webcast that day at 5:00 PM ET.

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta ® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) …

CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented by Dr. Gregory Sullivan, M.D.